<DOC>
	<DOCNO>NCT01303978</DOCNO>
	<brief_summary>Evaluation efficacy APD421 prevent nausea vomit cause cisplatin</brief_summary>
	<brief_title>Phase II Proof-of-concept Study APD421</brief_title>
	<detailed_description />
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<criteria>1 . Male female patient ≥ 18 year age 2 . Ability willingness give write informed consent 3 . Patients scheduled receive , day 1 chemotherapy , first cisplatin chemotherapy infusion dose 50 mg/m2 great 4 . Karnofsky performance score ≥ 60 % 5 . Adequate cardiac , hepatic renal function QTc interval &lt; 500 m Alanine aminotransferase ( ALT ) and/or aspartate aminotransferase ( AST ) &lt; 5 x upper limit normal ( ULN ) Bilirubin &lt; 3 x ULN Creatinine &lt; 2 x ULN 6 . Adequate haematological function Haemoglobin ≥ 9 g/dL White blood count ≥ 3.0 x 109/L Platelet count ≥ 100 x 109/L 7 . For female childbearing potential : ability willingness use highly effective form contraception ( e.g. , abstinence sexual intercourse , surgical sterilisation ( subject partner ) doublebarrier method contraception either intrauterine device ( IUD ) occlusive cap spermicide , conjunction partner 's use condom ) study period least 48 hour afterwards . 1 . Patients scheduled receive , prior 24 hour cisplatin , chemotherapeutic agent high moderate emetic risk , see Appendix 4 . 2 . Patients schedule receive paclitaxel docetaxel 3 . Patients undergoing abdominal pelvic irradiation within 48 hour prior screen schedule receive abdominal pelvic irradiation screen 24 hour cisplatin administration 4 . Patients receive APD421 indication within last 2 week 5 . Patients allergic APD421 excipients APD421 6 . Patients preexist vestibular disorder 7 . Patients treat regular antiemetic therapy include corticosteroid 8 . Patients receive inhaled corticosteroid , unless start one month prior expect date study entry 9 . Patients treated medication could induce torsades de pointes , include Class Ia antiarrhythmic agent quinidine , disopyramide , procainamide ; Class III antiarrhythmic agent amiodarone sotalol ; medication bepridil , cisapride , thioridazine , methadone , IV erythromycin , IV vincamine , halofantrine , pentamidine , sparfloxacin 10 . Patients treat xxx 11 . Patients receive benzodiazepine , unless stable dose least one month prior expect date study entry 12 . Patients preexist nausea vomit 24 hour receive cisplatin chemotherapy , e.g . anticipatory emesis 13 . Patients pregnant breast feed 14 . Patients history alcohol abuse 15 . Patients preexist , clinically significant cardiac arrhythmia 16 . Any concurrent disease illness , opinion investigator make patient unsuitable study 17 . Patients participate another study within previous 28 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
</DOC>